Table 1.
Clinicopathologic characteristics of the patients and samples used for the proteomic analysis and protein validation. No statistically significant difference for the distribution of cases was found.
| Variable | Cases used for protein identification (Discovery group) | Cases used for immunohistochemistry (Validation group) | p-value* | |||
|---|---|---|---|---|---|---|
| N | (%) | N | (%) | |||
| Sex | 0.773 | |||||
| Male | 11 | 50 | 14 | 56 | ||
| Female | 11 | 50 | 11 | 44 | ||
| Age (yrs) | 0.087 | |||||
| mean (range) | 53 | (39-88) | 48 | (38-64) | ||
| Histology | 0.862 | |||||
| Clear cell | 14 | 64 | 19 | 76 | ||
| Papillary | 2 | 9 | 2 | 8 | ||
| Chromophobe | 4 | 18 | 3 | 12 | ||
| Oncocytoma | 2 | 9 | 1 | 4 | ||
| Histological grade | 0.760 | |||||
| 1-2 | 9 | 45 | 9 | 36 | ||
| 3-4 | 11 | 55 | 16 | 64 | ||
| TNM stage | 0.224 | |||||
| I-II | 14 | 70 | 12 | 48 | ||
| III-IV | 6 | 30 | 13 | 52 | ||